Smith & Nephew announced that the third randomized controlled trial of its REGENETEN Bioinductive Implant has shown that patients with partial‑thickness rotator cuff tears recover functional independence faster than those treated with standard suture anchor repair. The study, published in the Orthopaedic Journal of Sports Medicine, reports that patients receiving the implant achieved sling removal, driving, and return to office duties 2.3, 2.3, and 1.7 weeks earlier, respectively, than the control group.
The trial enrolled 200 adults with symptomatic partial‑thickness tears, with a mean age of 55 years and a tear size range of 10–30 mm. Participants were randomized to receive either the REGENETEN implant or a conventional suture anchor repair. At 12 months, tendon healing on MRI was 92 % in the implant group versus 90 % in the control group, a difference that was not statistically significant but demonstrates comparable structural integrity while avoiding increased pain or complications.
The faster recovery metrics translate into a tangible benefit for patients and surgeons. Earlier sling removal and return to daily activities reduce the burden on rehabilitation services and improve patient satisfaction, while the similar healing rates mitigate concerns about long‑term durability. These findings reinforce the implant’s role as a viable adjunct in rotator cuff repair and support its continued adoption in the shoulder‑repair market, which is estimated at $875 million annually in the United States alone.
Smith & Nephew’s portfolio now includes the REGENETEN implant, the Q‑FIX All‑Suture Anchor, the AETOS Shoulder System, and the recently acquired Tendon Seam technology from Integrity Orthopaedics. The combined offering positions the company to address the high re‑tear rates that plague traditional repair techniques and to capture a larger share of the growing sports‑medicine and shoulder‑repair segments.
"We conducted a randomized controlled study of patients with symptomatic partial‑thickness rotator cuff tears and found that those treated with the tendon‑sparing REGENETEN Bioinductive Implant recovered functional independence much faster than patients treated with standard surgery," said Dr. Allan Wang, Clinical Professor of Orthopedic Surgery at the University of Western Australia. "Time to sling removal, return to driving, office duties, and household tasks all occurred sooner with the REGENETEN Bioinductive Implant, without an increase in pain or compromise in tendon healing on 12‑month MRI scans."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.